Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese pharma tries to downplay appearance of hostile bid driven largely by interest in Ranexa.
You may also be interested in...
Astellas Turns Up Heat On Bid To Acquire CV Therapeutics
If Japanese pharma’s gambit fails, it could be in breach of contract with CVT and lose rights to Lexiscan.
Astellas Turns Up Heat On Bid To Acquire CV Therapeutics
If Japanese pharma’s gambit fails, it could be in breach of contract with CVT and lose rights to Lexiscan.
CV Therapeutics Again Declines Astellas $16 Per Share Purchase Offer
During its 2008 earnings call, biotech says Astellas offer was inadequate when first offered and even more so today.